EGFR R521K Polymorphism Is Not a Major Determinant of Clinical Cetuximab Resistance in Head and Neck Cancer

EGFR R521K Polymorphism Is Not a Major Determinant of Clinical Cetuximab Resistance in Head and Neck Cancer

Background: Head and neck squamous cell carcinomas (HNSCCs) are among the most abundant malignancies worldwide. Patients with recurrent/metastatic disease undergo combination chemotherapy containing cetuximab, the monoclonal antibody used against the epidermal growth factor receptor (EGFR). Cetuxima...

Full description

Bibliographic Details
Main Authors: Mihály Cserepes, Györgyi A. Nelhűbel, Mónika Meilinger-Dobra, Adrienn Herczeg, Dóra Türk, Zita Hegedűs, Laura Svajda, Erzsébet Rásó, Andrea Ladányi, Kristóf György Csikó, István Kenessey, Árpád Szöőr, György Vereb, Éva Remenár, József Tóvári
Format: Article
Language:English
Published: MDPI AG 2022-05-01
Series:Cancers
Subjects:
EGFR
head and neck cancer
cetuximab
drug resistance
R521K
antibody-dependent cellular cytotoxicity
Online Access:https://www.mdpi.com/2072-6694/14/10/2407

Internet

https://www.mdpi.com/2072-6694/14/10/2407

Similar Items